Published in Cancer Weekly, June 20th, 2000
The purpose of these studies is to investigate the efficacy of XR5000 in a number of different tumor types in order to determine the best course of future clinical development.
Patients received XR5000 at a dose of 3,010 mg/m2 in a 120-hour intravenous infusion every three weeks. Response was assessed following...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.